TSX closed
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Get 200 free trades when you open an eligible CIBC Investor's Edge account.

  • 200 free stock & ETF trades
  • Unlimited commission-free trades on 180+ select ETFs
  • Offer ends September 30, 2026
Stocks/TSX-V/TTI

Thiogenesis Therapeutics Corp. (TTI : TSX-V)

Common Stock

$0.50

CAD

-0.01 (-1.96%)

Last updated: 2026-09-14

Get TTI alerts:

TTI

Thiogenesis Therapeutics Corp.

Source:WealthAwesomeWealthAwesome
$0.04 (-7.41%)
30 day period
$0.50$0.53$0.57Jun 30Aug 13Sep 14

Performance

1 Day

-1.96%

1 Week

+0.00%

1 Month

-9.09%

YTD

-23.08%

Key Statistics

Market Cap

$35.69M

52W High

$0.81

52W Low

$0.44

P/E Ratio

-

50 Day MA

$0.54

200 Day MA

$0.56

Beta

0.56

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

Below 50 SMA

Price vs 200-Day SMA

Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
9/14/2026$0.51$0.51$0.50$0.50$0.5043,000
9/11/2026$0.52$0.52$0.51$0.51$0.5128,000
9/10/2026$0.52$0.52$0.51$0.51$0.5126,500
9/9/2026$0.53$0.54$0.52$0.54$0.5436,650
9/8/2026$0.57$0.57$0.52$0.52$0.5220,200
9/4/2026$0.50$0.50$0.50$0.50$0.5011,500
9/3/2026$0.51$0.51$0.50$0.51$0.51156,000
9/2/2026$0.52$0.52$0.52$0.52$0.521,000
8/31/2026$0.55$0.55$0.54$0.54$0.542,315
8/24/2026$0.52$0.52$0.51$0.51$0.5113,500

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on TTI's historical volatility

HistoricalForecast68%95%
C$0.19C$0.34C$0.48C$0.63C$0.78C$0.92TodayApr 6Jun 9Sep 14Oct 27Dec 10Jan 22

30-Day Vol

63.6%

Annualized

90-Day Vol

59.9%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$0.42

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.47C$0.38C$0.59
60 trading daysC$0.44C$0.33C$0.61
90 trading daysC$0.42C$0.29C$0.61

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.

Financials

Revenue (TTM)
$0
EBITDA
-
Profit Margin
0.00%
ROE (TTM)
-181.53%
EPS (Diluted)
-0.12
Book Value
0.10

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About TTI

Market movers

Recent TSX-V movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
EKGCardioComm Solutions Inc.$0.01+100.00%
THY-PThermopylae Capital Inc.$0.07+100.00%
BLUBluEnergies Ltd.$4.25+84.78%
MURMurchison Minerals Ltd$0.24+50.00%
CPSCanadian Premium Sand Inc$0.12+50.00%
PCQPetrolympic Ltd$0.17+41.67%
AUR-HAurora Royalties Inc$0.04+40.00%
CCMMCoyote Copper Mines Inc.$0.66+36.08%

TTI.V news timeline

3 articles covering TTI.V, most recent first

Latest

Why Thiogenesis Therapeutics Corp. stock is rising today

Stocks

Advertisement